Free Trial

Encompass Health (EHC) Stock Forecast & Price Target

Encompass Health logo
$94.19 -0.26 (-0.28%)
(As of 05:45 PM ET)

Encompass Health - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
0
Buy
11

Based on 11 Wall Street analysts who have issued ratings for Encompass Health in the last 12 months, the stock has a consensus rating of "Buy." Out of the 11 analysts, 9 have given a buy rating, and 2 have given a strong buy rating for EHC.

Consensus Price Target

$107.11
13.72% Upside
According to the 11 analysts' twelve-month price targets for Encompass Health, the average price target is $107.11. The highest price target for EHC is $117.00, while the lowest price target for EHC is $95.00. The average price target represents a forecasted upside of 13.72% from the current price of $94.19.
Get the Latest News and Ratings for EHC and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Encompass Health and its competitors.

Sign Up

EHC Analyst Ratings Over Time

TypeCurrent Forecast
12/24/23 to 12/23/24
1 Month Ago
11/24/23 to 11/23/24
3 Months Ago
9/25/23 to 9/24/24
1 Year Ago
12/24/22 to 12/24/23
Strong Buy
2 Strong Buy rating(s)
2 Strong Buy rating(s)
2 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
9 Buy rating(s)
9 Buy rating(s)
8 Buy rating(s)
5 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$107.11$107.11$100.38$77.60
Forecasted Upside13.72% Upside5.92% Upside5.37% Upside15.51% Upside
Consensus Rating
Buy
Buy
Buy
Buy

EHC Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

EHC Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Encompass Health Stock vs. The Competition

TypeEncompass HealthMedical CompaniesS&P 500
Consensus Rating Score
3.18
2.81
2.51
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside14.46% Upside26,134.84% Upside14.68% Upside
News Sentiment Rating
Positive News

See Recent EHC News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
10/30/2024Royal Bank of Canada
4 of 5 stars
 Boost TargetOutperform ➝ Outperform$105.00 ➝ $110.00+9.49%
10/30/2024Truist Financial
2 of 5 stars
 Reiterated RatingBuy ➝ Buy$108.00 ➝ $116.00+15.83%
10/29/2024Barclays
3 of 5 stars
 Boost TargetOverweight ➝ Overweight$109.00 ➝ $116.00+24.56%
10/29/2024KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Gillmor
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOverweight ➝ Overweight$115.00 ➝ $117.00+25.63%
9/25/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
A. Rice
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$100.00 ➝ $110.00+14.17%
8/6/2024Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$105.00 ➝ $105.00+24.38%
7/10/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
W. Mayo
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
7/10/2024Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$100.00+19.09%
4/26/2024Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingStrong-Buy ➝ Strong-Buy$85.00 ➝ $95.00+14.89%
4/25/2024Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$93.00 ➝ $95.00+14.85%
2/7/2024William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Haase
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
8/4/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$76.00 ➝ $80.00+13.35%
5/1/2023Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$70.00 ➝ $73.00+12.50%
4/28/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$69.00 ➝ $74.00+16.65%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 10:37 PM ET.


EHC Forecast - Frequently Asked Questions

According to the research reports of 11 Wall Street equities research analysts, the average twelve-month stock price forecast for Encompass Health is $107.11, with a high forecast of $117.00 and a low forecast of $95.00.

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Encompass Health in the last twelve months. There are currently 9 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EHC shares.

According to analysts, Encompass Health's stock has a predicted upside of 13.72% based on their 12-month stock forecasts.

Over the previous 90 days, Encompass Health's stock had 1 upgrade by analysts.

Encompass Health has been rated by research analysts at Barclays, KeyCorp, Royal Bank of Canada, Truist Financial, and UBS Group in the past 90 days.

Analysts like Encompass Health more than other "medical" companies. The consensus rating for Encompass Health is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how EHC compares to other companies.


This page (NYSE:EHC) was last updated on 12/23/2024 by MarketBeat.com Staff
From Our Partners